KCTBASE

The effect of radiotherapy in liver-confined but non-resectable Barcelona Clinic Liver Cancer stage C large hepatocellular carcinoma.

Yoon, Hong In; Jung, Inkyung; Han, Kwang-Hyub; Seong, Jinsil

Oncotarget
2016Sep ; 7 ( 38 ) :62715-62725.

PMID : 27486881

저자 상세정보

Yoon, Hong In -
Jung, Inkyung -
Han, Kwang-Hyub -
Seong, Jinsil -

ABSTRACT

BACKGROUND AND AIMS: Clinical trials to determine the efficacy of radiotherapy (RT) in liver-confined but non-resectable Barcelona Clinic Liver Cancer (BCLC) stage C hepatocellular carcinoma (HCC) are scarce. We aimed to determine the benefit of RT in such tumors and investigated large HCC tumors.

METHODS: HCC data from the Korea Central Cancer Registry recorded from 2008 to 2010 were used. A total of 593 patients met our inclusion criteria; 67 were treated with RT while the remainder made up the non-RT group. Fifty-two RT recipients underwent combination treatments within 4 weeks after the first RT treatment, and were defined as the combination RT group. We performed propensity score matching (PSM) to compare the RT or combination RT groups with the non-RT group. The endpoint was overall survival (OS).

RESULTS: Median follow-up time for surviving patients was 48 months. After PSM, there was no difference in OS between the RT and non-RT groups or between the combination RT and non-RT groups. However, the combination RT group had a longer median survival time (MST) (10.7 vs. 6.9 months, respectively). Next, we conducted PSM between the combination RT and non-RT groups in patients with tumor sizes ??0 cm; MST was significantly longer in the former group (10.1 vs. 5.4 months, respectively; bootstrap 95% confidence interval of the difference in MST: 0.2-11.8).

CONCLUSIONS: As a combined modality, RT is a plausible therapeutic option for liver-confined but non-resectable BCLC stage C large HCC patients.

BCLC stage C; large hepatocellular carcinoma; median survival time; propensity score matching; radiotherapy

링크

PubMed

주제코드

주제명(Target field)

연구대상(Population)

연구참여(Sample size)

대상성별(Gender)

질병특성(Condition Category)

연구환경(Setting)

연구설계(Study Design)

연구기간(Period)

중재방법(Intervention Type)

중재명칭(Intervention Name)

키워드(Keyword)

유효성결과(Recomendation)

There was no difference in OS between the RT and non-RT groups or between the combination RT and non-RT groups, but However, the combination RT group had a longer median survival time (MST) (10.7 vs. 6.9 months, respectively).

연구비지원(Fund Source)

근거수준평가(Evidence Hierarchy)

출판년도(Year)

참여저자수(Authors)

대표저자

DOI

10.18632/oncotarget.10908

KCD코드

ICD 03

건강보험코드